KV agrees to FDA plan for resuming work

KV Pharmaceuticals said it has entered a consent decree with the FDA that provides for KV's return to manufacturing and distribution of its products, provided it satisfies a series of requirements. As you know, KV stopped making products in January and cut its workforce in half last month. Release

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.